Global Erectile Dysfunction Treatment Market - Focused Insights 2024-2029

The global erectile dysfunction treatment market, valued at $4,727.51 million in 2023, is expected to slightly decline to $4,467.49 million by 2029, registering a negative CAGR of -0.94%. This decrease is primarily due to the expiration of patents for major ED drugs like Viagra, Cialis, and Levitra. Despite this, the market is maintaining sustainable growth with an influx of generic manufacturers and the ongoing prevalence of the disease worldwide.

Key drivers for this market include the high prevalence of erectile dysfunction, often linked with chronic diseases such as diabetes, prostate cancer, and cardiovascular diseases. Globally, ED is a widespread male sexual disorder, but it suffers from low diagnostic and treatment rates. However, rising awareness and patient willingness to seek medical help are expected to propel market growth.

A notable shift in the market is the emerging popularity of novel therapies like topical gels, exemplified by Vitaros by Seelos Therapeutics, offering advantages like ease of use and rapid action. PDE-5 inhibitors are preferred as first-line therapy, with advancements in oral PDE-5 inhibitors, including innovative oral transmucosal medicine delivery methods, gaining traction.

The aging population significantly contributes to market demand, with ED prevalence increasing with age. Penile injections, offering reliable rigidity and rapid onset of erection, are recommended for patients unable to take oral medications.

The market also sees innovations like shock wave therapy and magnetic therapy, boosting growth. The highest consumption of ED drugs and devices is observed in the US and Europe, with growing demand expected in developing regions, especially APAC, due to a large unsatisfied patient pool and increasing awareness.

Retail pharmacies lead the market due to easy access to ED drugs. Penile implants and vacuum constriction devices (VCDs) are gaining popularity for their effectiveness and reliability.

North America holds the largest market share, with rising stress levels and chronic conditions like diabetes and cardiovascular diseases contributing to increased ED incidence. The prevalence of ED in Europe is expected to rise, driving the treatment pool.

In APAC, factors such as a large patient population, well-established healthcare infrastructure, and rising healthcare expenditure contribute to market growth. The Middle East & Africa is also expected to follow a similar growth trend.

The market is characterized by the presence of pharmaceutical companies, generic manufacturers, and device manufacturers, with leading players like Pfizer, Boston Scientific, Eli Lilly and Company, Coloplast, and Bayer dominating the market. These companies are pursuing strategies like acquisitions to expand their presence and product portfolios.

Key Highlights:

• The global erectile dysfunction treatment market was valued at $4,727.51 million in 2023 and is expected to reach $4,467.49 million by 2029, registering a negative CAGR of -0.94%. The market reach is mainly attributed to the rising prevalence of erectile dysfunction and associated chronic diseases such as diabetes, benign prostate hyperplasia, prostate cancer, and CVDs, which can, in turn, pose high-risk factors for the occurrence of disease, are key factors for the erectile dysfunction treatment market.
• In 2023, North America and Europe dominated the market with a market share of 33.63% and 29.05%, respectively. APAC is expected to be the fastest-growing market for erectile dysfunction treatment market in terms of revenue, during the forecast period with a CAGR of 2.70%.
• Based on product, the drugs segment dominated the market over the devices segment and accounted for a market share of 79.08%, whereas the devices segment accounted for a 20.92% share. However, during the forecast period, the devices segment is likely to witness the highest incremental and absolute growth of $252.58 million and 25.54%.
• The route of administration (RoA) segment of ED drugs is sub-segmented into oral drugs, penile injections, and topical drugs. Among the three sub-segments, oral drugs occupied the largest share, which is attributed to the high adoption of branded drugs. Overall, 92.57% was occupied by oral drugs, followed by penile injections at 4.70% and topical drugs at 2.73%.
• Rising awareness, growing patient willingness to demand medical assistance for disease care and management, and the increasing presence of favorable guidelines that recommend the use of drugs and devices for the treatment of ED are expected to propel market growth during the forecast period.
• Bayer, Pfizer, Eli Lilly and Company, Coloplast, and Boston Scientific are some of the leading players currently dominating the global erectile dysfunction treatment market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the ED treatment market and gain access to commercially launched products.